Disruptions of the AR pathway consist of AR point mutations, affecting both NTD and LBD, truncated variants, and gene amplifications, all of which confer selective advantage to prostate cancer cells with different mechanisms [13]. The gene discussed is AR; the disease is prostate cancer.